AN2 Therapeutics Q3 2026 Results, PMB Study Starts, and New HPP Candidate
AN2 Therapeutics reported Q3 financial results, received IND clearance for epetraborole in polycythemia vera, and initiated enrollment, signaling progress in its boron chemistry pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed